MedPath

Furosemide

Generic Name
Furosemide
Brand Names
Furoscix, Lasix
Drug Type
Small Molecule
Chemical Formula
C12H11ClN2O5S
CAS Number
54-31-9
Unique Ingredient Identifier
7LXU5N7ZO5
Background

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.

Indication

Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.

Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.

Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.

Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.

Associated Conditions
Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion

A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects

First Posted Date
2023-03-14
Last Posted Date
2023-07-13
Lead Sponsor
AstraZeneca
Target Recruit Count
6
Registration Number
NCT05768360
Locations
🇩🇪

Research Site, Berlin, Germany

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Not Applicable
Completed
Conditions
Liver Cirrhosis
Interventions
First Posted Date
2023-02-23
Last Posted Date
2025-01-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
28
Registration Number
NCT05741372
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Prolonged Intravenous Therapy Versus Early Initiation of an Oral Loop Diuretic in Decompensated Heart Failure

First Posted Date
2022-12-15
Last Posted Date
2025-02-20
Lead Sponsor
Jan Kochanowski University
Target Recruit Count
200
Registration Number
NCT05652322
Locations
🇵🇱

Wojewodzki Szpital Zespolony Klinika Nefrologii, Kielce, Poland

🇵🇱

Wojewódzki Szpital Zespolony OIOK, Kielce, Poland

🇵🇱

Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Oddzial Kardiologii, Łódź, Poland

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

Phase 3
Recruiting
Conditions
BPH With Urinary Obstruction
BPH
Hematuria
Same Day Discharge
Interventions
First Posted Date
2022-11-17
Last Posted Date
2023-09-13
Lead Sponsor
Northwestern University
Target Recruit Count
138
Registration Number
NCT05620784
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

Furosemide Stress Test to Predict Successful Liberation From RRT

Recruiting
Conditions
Acute Kidney Injury
Interventions
First Posted Date
2022-11-10
Last Posted Date
2024-12-13
Lead Sponsor
Centre Hospitalier Universitaire Vaudois
Target Recruit Count
60
Registration Number
NCT05612490
Locations
🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland

Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH

Not Applicable
Recruiting
Conditions
Pulmonary Arterial Hypertension
Randomized Controlled Trial
Interventions
First Posted Date
2022-10-06
Last Posted Date
2022-10-06
Lead Sponsor
Chinese Pulmonary Vascular Disease Research Group
Target Recruit Count
100
Registration Number
NCT05569655
Locations
🇨🇳

center of pulmonary vascular disease, Fuwai hospital, Beijing, China

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Phase 1
Active, not recruiting
Conditions
Tumor
Melanoma
Metastatic Melanoma
Interventions
First Posted Date
2022-07-22
Last Posted Date
2025-04-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
21
Registration Number
NCT05470283
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

Early Phase 1
Recruiting
Conditions
Interaction
Endogenous Biomarkers
Interventions
First Posted Date
2022-05-09
Last Posted Date
2024-12-19
Lead Sponsor
Washington State University
Target Recruit Count
32
Registration Number
NCT05365451
Locations
🇺🇸

Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, United States

Optimized Treatment of Pulmonary Edema or Congestion

Phase 4
Recruiting
Conditions
Pulmonary Edema
Congestive Heart Failure
Acute Heart Failure
Interventions
First Posted Date
2022-03-11
Last Posted Date
2024-12-19
Lead Sponsor
Johannes Grand
Target Recruit Count
1104
Registration Number
NCT05276219
Locations
🇩🇰

Nordsjællands Hospital, Hillerød, Denmark

🇩🇰

Bispebjerg Hospital, Copenhagen, Denmark

🇩🇰

Hvidovre Hospital, Copenhagen, Denmark

and more 1 locations

Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi

Phase 3
Conditions
Urolithiasis
Nephrolithiasis
Urinary Calculi
Ureterolithiasis
Interventions
Other: Conventional Treatment
First Posted Date
2022-03-08
Last Posted Date
2022-03-08
Lead Sponsor
Shiraz University of Medical Sciences
Target Recruit Count
500
Registration Number
NCT05270421
Locations
🇮🇷

Shahid Faghihi Hospital, Shiraz, Fars, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath